M. Stahl (Heidelberg, Germany), J. Davies (London, United Kingdom)
Synergistic activity of colistin in combination with N-acetylcysteine against colistin-resistant Acinetobacter Baumannii grown in biofilms F. Sergio (Bresso, Italy), S. Pollini (Firenze, Italy), S. Boncompagni (Siena, Italy), T. Di Maggio (Siena, Italy), S. Aliberti (Milano, Italy), F. Blasi (Milano, Italy), L. Pallecchi (Firenze, Italy), G. Rossolini1 (Firenze, Italy)
| |
Safety and efficacy of intravenous (IV) Fosfomycin in adult cystic fibrosis patients C. Biglia (Orbassano (TO), Italy), C. Bena (Orbassano (TO), Italy), G. Bonizzoni (Orbassano (TO), Italy), M. Bellocchia (Orbassano (TO), Italy), A. Grande (Orbassano (TO), Italy), F. Traversa (Orbassano (TO), Italy), E. Clivati (Orbassano (TO), Italy), G. Bandelli (Orbassano (TO), Italy), S. Demichelis (Orbassano (TO), Italy), C. Albera (Orbassano (TO), Italy), B. Messore (Orbassano (TO), Italy)
| |
Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis M. Di Paolo (London, United Kingdom), K. Dave (London, United Kingdom), A. Vijayasingam (London, United Kingdom), R. Sheth (London, United Kingdom), E. Luke (London, United Kingdom), A. Scourfield (London, United Kingdom), L. Nwankwo (London, United Kingdom), S. Schelenz (London, United Kingdom), J. Elborn (London, United Kingdom), D. Armstrong-James (London, United Kingdom), A. Shah (London, United Kingdom)
| |
The prevalence and diversity of fungi in respiratory samples of cystic fibrosis patients – a Dutch, nationwide, prospective, multicentre study T. Engel (Nijmegen, Netherlands), L. Slabbers (Nijmegen, Netherlands), C. De Jong (Nijmegen, Netherlands), W. Melchers (Nijmegen, Netherlands), F. Hagen (Nijmegen, Netherlands), P. Verweij (Nijmegen, Netherlands), P. Merkus (Nijmegen, Netherlands), J. Meis (Nijmegen, Netherlands)
| |
Identification of disease specific biomarkers by exhalomics using Secondary Electrospray Ionisation High-resolution Mass Spectrometry (SESI-HRMS) in children with cystic fibrosis K. Heschl (ZH, Switzerland), N. Haas-Baumann (ZH, Switzerland), R. Weber (ZH, Switzerland), A. Baghdasaryan (ZH, Switzerland), S. Micic (ZH, Switzerland), F. Singer (ZH, Switzerland), R. Zenobi (ZH, Switzerland), T. Bruderer (ZH, Switzerland), A. Möller (ZH, Switzerland)
| |
Detection of Pseudomonas aeruginosa infection in cystic fibrosis patients by eNose technology M. Lammers (Amsterdam, Netherlands), R. Kos (Amsterdam, Netherlands), R. De Vries (Amsterdam, Netherlands), P. Brinkman (Amsterdam, Netherlands), J. Dagelet (Amsterdam, Netherlands), N. Rutjes (Amsterdam, Netherlands), C. Majoor (Amsterdam, Netherlands), S. Terheggen-Lagro (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands), P. Sterk (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), A. Neerincx & The Amsterdam Cf Research Group (Amsterdam, Netherlands)
| |
Reduced uptake of inhaled carbon in airway macrophages from children with cystic fibrosis N. Liu (London, United Kingdom), L. Miyashita (London, United Kingdom), J. Grigg (London, United Kingdom)
| |
Retrospective analysis of treatment with Ivacaftor/Lumacaftor in patients with cystic fibrosis at the Munich Cystic Fibrosis Centers S. Naehrig (Munich, Germany), P. Mertsch (Munich, Germany), M. Griese (Munich, Germany), M. Kappler (Munich, Germany), R. Huber (Munich, Germany)
| |
Effects of Lumacaftor-Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis S. Gräber (Heidelberg, Germany), C. Dopfer (Hannover, Germany), L. Naehrlich (Giessen, Germany), L. Gyulumyan (Hannover, Germany), H. Scheuermann (Heidelberg, Germany), S. Hirtz (Heidelberg, Germany), S. Wege (Heidelberg, Germany), H. Mairbaeurl (Heidelberg, Germany), M. Dorda (Hannover, Germany), R. Hyde (Hannover, Germany), A. Bagheri-Hanson (Giessen, Germany), C. Rueckes-Nilges (Giessen, Germany), S. Fischer (Hannover, Germany), M. Mall (Heidelberg, Germany), B. Tuemmler (Hannover, Germany)
| |
Noninvasive ventilation (NPPV) affects Pulmonary Exacerbation (PE) rate in Cystic Fibrosis children (CFc). L. Appendini (Saluzzo (CN), Italy), L. Ronco (Torino, Italy), G. Ferreyra (Torino, Italy), I. Esposito (Torino, Italy), E. Bignamini (Torino, Italy)
| |
Exercise capacity in patients with cystic fibrosis at 6 and 12 months after lung transplantation M. Damin (Padova, Italy), M. De Toni (Padova, Italy), M. Marchi (Padova, Italy), G. Foltran (Padova, Italy), E. Bazzan (Padova, Italy), G. Turato (Padova, Italy), M. Saetta (Padova, Italy), M. Cosio (Montreal , Canada)
| |
Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomized, controlled, crossover trial T. Radtke (Zurich, Switzerland), L. Boeni (Zurich, Switzerland), P. Bohnacker (Zurich, Switzerland), M. Maggi-Bebba (Zurich, Switzerland), P. Fischer (Zurich, Switzerland), S. Kriemler (Zurich, Switzerland), C. Benden (Zurich, Switzerland), H. Dressel (Zurich, Switzerland)
| |
Risk factors for early lung function decline in young children with Cystic Fibrosis J. Balinotti (Buenos Aires , Argentina), D. Chang (Buenos Aires , Argentina), V. Rodriguez (Buenos Aires , Argentina), S. Lubovich (Buenos Aires , Argentina), S. Zaragoza (Buenos Aires , Argentina), N. Escobar (Buenos Aires , Argentina), C. Kofman (Buenos Aires , Argentina), L. Perez (Buenos Aires , Argentina), V. Ardiles (Buenos Aires , Argentina), A. Teper (Buenos Aires , Argentina)
| |
The TLR4 regulator miR-21 is downregulated in the paediatric cystic fibrosis airway A. Glasgow (Dublin, Ireland), S. Vencken (Dublin, Ireland), C. De Santi (Dublin, Ireland), R. Raoof (Dublin, Ireland), D. Henshall (Dublin, Ireland), B. Linnane (Limerick, Ireland), P. Mcnally (Dublin, Ireland), C. Greene (Dublin, Ireland)
| |
HspB5 in Cystic Fibrosis F. Degrugillier (Créteil, France), X. Decrouy (Créteil, France), V. Prulière-Escabasse (Créteil, France), C. Jiang (Toronto, Canada), D. Rotin (Toronto, Canada), P. Fanen (Créteil, France), S. Simon (Créteil, France)
| |
Large phenotypic spectrum associated with two new deep intronic variants on the CFTR gene A. BERGOUGNOUX (Montpellier, France), K. Deletang (Montpellier, France), J. Varilh (Montpellier, France), F. Houriez (Paris, France), J. Altieri (Montpellier, France), M. Koenig (Montpellier, France), C. Férec (Brest, France), C. Mireille (Montpellier, France), T. Bienvenu (Paris, France), M. Audrezet (Brest, France), A. Pagin (Lille, France), E. Girodon (Paris, France), C. Raynal (Montpellier, France), M. Taulan-Cadars (Montpellier, France)
| |
PRO-INFLAMMATORY ACTIVITY AND OXIDATIVE STRESS ON A LINE OF CYSTIC FIBROSIS (CF) HUMAN RESPIRATORY EPITHELIUM J. Figueroa (Buenos Aires, Argentina), M. Clauzure (Buenos Ai, Argentina), Á. Valdivieso (Buenos Ai, Argentina), M. Massip-Copiz (Buenos Ai, Argentina), C. Mori (Buenos Ai, Argentina), A. Dugour (Buenos Aires, Argentina), D. Primrose (Buenos Aires, Argentina), T. Santa Coloma (Buenos Aires, Argentina)
| |
Plasma ceramides and sphingomyelins increase in primary ciliary dyskinesia but decrease in cystic fibrosis D. Bal Topcu (Ankara, Turkey), G. Tugcu (Ankara, Turkey), F. Ozcan (Antalya, Turkey), M. Aslan (Antalya, Turkey), S. Esref (Ankara, Turkey), M. Gharibzadeh Hizal (Ankara, Turkey), E. Elmas Yalcin (Ankara, Turkey), D. Dogru Ersoz (Ankara, Turkey), U. Ozcelik (Ankara, Turkey), N. Kiper (Ankara, Turkey), I. Lay (Ankara, Turkey), Y. Oztas (Ankara, Turkey)
| |